Describe the various methods in pharmacoeconomic analysis and discuss in detail the essentiality of the same for 10 marks for MD pharmacology
I'll read the medical library skill first, then search for pharmacoeconomics content in parallel.
Reading File
Now searching the library in parallel for pharmacoeconomics content:
Finding Sources
Finding Sources
Let me search more specifically for pharmacoeconomic methods:
Finding Sources
Finding Sources
Reading File
Let me read the Sabiston Surgery section on cost-effectiveness analysis and search for more pharmacoeconomics content:
Reading File
Finding Sources
Finding Sources
Excellent content found. Let me now read the Yamada gastroenterology section on forms of economic analysis and the Rheumatology section, which seem comprehensive:
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive content from multiple authoritative textbooks. Let me also check Park's Preventive Medicine for the pharmacoeconomics section, which is very relevant for MD Pharmacology exams:
Reading File
I now have comprehensive, authoritative content from multiple textbooks. Let me compose the full answer for a 10-mark MD Pharmacology essay.
Pharmacoeconomic Analysis: Methods and Essentiality
INTRODUCTION
Pharmacoeconomics is the scientific discipline that measures and compares the costs and outcomes (clinical, economic, and humanistic) of pharmaceutical products and services. It applies the principles of health economics specifically to drug therapy, helping clinicians, policy-makers, insurers, and healthcare systems make rational decisions about drug selection, formulary management, and resource allocation.
As healthcare costs have grown from $1.4 trillion (2000) to $3.5 trillion (2017) in the US alone, representing 18% of GDP, the ability to identify management strategies that are both effective and cost-effective has become imperative for clinicians. - Yamada's Textbook of Gastroenterology
TYPES OF COSTS IN PHARMACOECONOMICS
Before understanding the analytical methods, it is essential to recognise the categories of costs involved:
1. Direct Medical Costs - hospitalizations, drugs, procedures, physician visits, laboratory tests, devices, equipment, and home care paid by third-party payers or out-of-pocket.
2. Direct Non-Medical Costs - transportation, lodging, and caregiver time associated with receiving treatment.
3. Indirect/Productivity Costs - loss of employment due to morbidity (disability, absenteeism, reduced on-the-job productivity) or premature mortality. For example, families of children with juvenile rheumatoid arthritis incur significant informal caregiver costs. - Rheumatology, Elsevier
4. Intangible Costs - pain, suffering, and deterioration in quality of life. These are difficult to quantify monetarily.
An important distinction: "charges" (what is billed) differ from "costs" (the actual resources consumed). True costs reflect the opportunity cost - resources spent on one intervention cannot be used elsewhere. - Yamada's Textbook of Gastroenterology
PERSPECTIVES IN PHARMACOECONOMIC ANALYSIS
The perspective chosen determines which costs are included:
- Societal perspective (broadest, most comprehensive): includes all direct, indirect, and intangible costs
- Payer/Insurer perspective: only costs borne by the payer
- Patient perspective: out-of-pocket costs only
- Healthcare system/Hospital perspective: institutional costs only
- Employer perspective: productivity and absenteeism costs
The societal perspective is theoretically ideal but practically difficult; most economic models use the third-party payer perspective. - Yamada's Textbook of Gastroenterology
METHODS OF PHARMACOECONOMIC ANALYSIS
1. Cost-Minimization Analysis (CMA)
Definition: The simplest form of pharmacoeconomic analysis. It identifies the least expensive alternative when two or more interventions have been shown (or are assumed) to produce equivalent clinical outcomes.
Method: The total economic resources expended by each strategy are summed, considering disease costs, complications, and treatment costs. Results are expressed in monetary units.
Example: Comparing two generic formulations of the same drug with proven bioequivalence - if outcomes are identical, the cheaper option is preferred.
Limitation: Because alternative health interventions rarely have equivalent effectiveness, CMA is an uncommon and rarely appropriate comparative analysis. If clinical benefits differ even slightly, CMA is invalid and more complex methods are required. - Yamada's Textbook of Gastroenterology; Rheumatology (Elsevier)
2. Cost-Benefit Analysis (CBA)
Definition: An economic evaluation in which both costs AND health benefits/outcomes are expressed in the same monetary unit (e.g., rupees or dollars).
Method:
- Costs are calculated as in cost minimization
- Health benefits are translated into a monetary amount (e.g., value of a life saved, days of work recovered)
- Net Present Value (NPV) = Economic Benefit - Economic Cost
- If NPV is positive, the benefit exceeds the cost; policy-makers choose programs with the highest NPV
Advantage: Allows comparison of programs across entirely different sectors (healthcare vs. education vs. defense), since everything is in the same monetary unit.
Major Limitation: Placing a monetary value on human life and health outcomes is ethically contentious and methodologically difficult. Benefits in healthcare (e.g., years of suffering prevented) cannot always be expressed in rupees. This limits its widespread adoption in clinical pharmacoeconomics. - Park's Textbook of Preventive Medicine; Rheumatology (Elsevier)
3. Cost-Effectiveness Analysis (CEA)
Definition: An economic evaluation that simultaneously measures both the outcomes and costs of alternative interventions when outcomes differ. Rather than converting health benefits to money, outcomes are expressed as natural clinical units.
Method:
- Costs remain in monetary units
- Benefits are expressed as clinically meaningful outcomes: lives saved, life-years gained, cases cured, symptom-free days, blood pressure reduction, etc.
- Results are reported as cost per unit of outcome: e.g., "cost per life-year gained," "cost per case of TB prevented"
Incremental Cost-Effectiveness Ratio (ICER):
ICER = (Cost of Intervention A - Cost of Intervention B) / (Effectiveness of A - Effectiveness of B)
The ICER tells how much additional cost is incurred to gain one additional unit of outcome by choosing the more effective (but more costly) intervention. Lower ICERs are more desirable - they indicate better value for money. - Sabiston Textbook of Surgery; Yamada's Textbook of Gastroenterology
Four ICER Outcomes possible:
- Higher cost + lower effectiveness: new intervention is dominated - do not adopt
- Lower cost + higher effectiveness: new intervention is dominant (cost-saving) - adopt
- Lower cost + lower effectiveness: calculate ICER to decide
- Higher cost + higher effectiveness: calculate ICER, compare against willingness-to-pay threshold
Limitation: CEA cannot directly compare programs with different outcome measures (e.g., cost per ACR20 response in RA vs. cost per MI prevented) - this is resolved by cost-utility analysis. - Rheumatology, Elsevier
4. Cost-Utility Analysis (CUA)
Definition: A special and most commonly used form of cost-effectiveness analysis that uses a standardized, quality-adjusted effectiveness measure - the Quality-Adjusted Life Year (QALY) - enabling comparison across entirely different diseases and interventions.
The QALY:
QALY = Life-years gained × Health Utility Weight (0 to 1)
- Health utility weight = 1 represents perfect health
- Health utility weight = 0 represents death
- Intermediate states (e.g., dialysis, severe disability) are assigned intermediate values between 0 and 1, based on patient preferences
Cost-Utility Ratio = Costs ($) / QALYs gained
Method:
- Costs are in monetary units
- Benefits are expressed in QALYs
- Results expressed as "cost per QALY gained"
- The ICER compares competing interventions: incremental cost per QALY gained
Willingness-to-Pay Threshold:
- Interventions costing less than approximately $100,000 per QALY are generally considered cost-effective by current US standards
- In the UK, NICE uses a threshold of £20,000-£30,000 per QALY
- Example: coronary artery bypass surgery vs. PCI for coronary artery disease had an ICER of approximately $30,000/QALY - deemed cost-effective. - Sabiston Textbook of Surgery
Advantage over CEA: CUA allows cross-disease comparison - the incremental cost of a biologic drug for RA can now be directly compared with the incremental cost of a new antihypertensive, because both are expressed as cost per QALY gained. This is why CUA has become the predominant method for Health Technology Assessment globally. - Rheumatology, Elsevier; Cummings Otolaryngology
5. Cost-Consequence Analysis (CCA)
Definition: A form of economic analysis in which all components of costs and benefits of competing programs are calculated and presented individually, without any attempt to aggregate or combine them into a single summary metric.
Method: Decision-makers receive a disaggregated list of all cost and outcome components side by side, and make their own value judgments about relative importance.
Advantage: Preserves the full complexity of outcomes without the reductionism of a single ratio. Useful when multiple different stakeholders weigh outcomes differently.
Limitation: Does not provide a single actionable decision metric, making comparisons difficult. - Yamada's Textbook of Gastroenterology
6. Budget Impact Analysis (BIA)
This assesses the financial consequences of adopting a new drug or therapy on the budget of a healthcare payer or system over a defined time period. While not strictly a pharmacoeconomic "method" in the analytical sense, it is an essential companion to CEA/CUA for policy decisions, since an intervention may be cost-effective per QALY yet still unaffordable at scale. - Rheumatology, Elsevier
ANALYTICAL TOOLS AND SUPPORTING METHODS
Decision Modeling - Markov Models
Complex pharmacoeconomic analyses use Markov models, which simulate patient outcomes over time by assuming that patients are always in one of a finite number of discrete health states (e.g., "disease-free," "stable disease," "relapsed," "dead"), each with assigned costs and utilities. Transitions between states occur probabilistically using event rates from existing literature. This allows cost-effectiveness to be projected over a patient's lifetime based on available shorter-term trial data. - Sabiston Textbook of Surgery
Sensitivity Analysis
A critical step in any pharmacoeconomic model. It tests whether the conclusions of the analysis change when parameter estimates are varied within clinically plausible ranges:
- One-way sensitivity analysis: one variable varied at a time
- Two-way or multi-way: two or more variables varied simultaneously
- Monte Carlo simulation: thousands of random combinations of all variables simultaneously - produces a probabilistic range of outcomes
Variables to which a model is sensitive identify priority areas for further research. - Yamada's Textbook of Gastroenterology
Discounting
Economic analyses must account for time preferences: people (and health systems) prefer benefits now and costs in the future. Discounting adjusts both future costs and future health benefits to their present value, avoiding the artifact that delaying any intervention always appears more cost-effective. - Yamada's Textbook of Gastroenterology
ESSENTIALITY OF PHARMACOECONOMIC ANALYSIS
Pharmacoeconomics is not merely an academic exercise; it has direct, practical implications at every level of the healthcare system:
1. Rational Formulary Management
Hospital Formulary Committees and National Essential Medicines Lists use pharmacoeconomic data to decide which drugs to include. When two drugs with comparable efficacy are available, the one with a superior pharmacoeconomic profile (lower cost per outcome) is preferred. This is the direct application of CMA and CEA.
2. National Drug Policy and Health Technology Assessment (HTA)
Regulatory bodies like NICE (UK), CADTH (Canada), and in India the Health Technology Assessment India (HTAIn) mandate pharmacoeconomic evidence for drug reimbursement decisions. A new biologic may be clinically superior but if its ICER exceeds the societal willingness-to-pay threshold, it may not be recommended for universal coverage.
3. Prioritising Healthcare Resources in Low-Income Settings
In sub-Saharan Africa and lower-middle income countries like India, out-of-pocket payment is predominant. Newer medications are often not cost-effective in these settings. First-generation antipsychotics and TCAs have been shown to be more affordable and cost-effective than newer biologics in such contexts. - Kaplan & Sadock's Comprehensive Textbook of Psychiatry
4. Drug Approval and Pricing
Pharmacoeconomic evidence increasingly supplements clinical trial data in regulatory submissions. Pharmaceutical companies use it to justify pricing to payers and insurers, while payers use it to negotiate prices and define reimbursement conditions.
5. Clinical Decision-Making
CEA and CUA help surgeons and physicians make decisions by presenting cost-outcome trade-offs between competing interventions. For example, choosing between laparoscopic vs. open surgery, or deciding whether expensive biologic add-on therapy for RA is justified, can be guided by ICER data.
6. Prevention vs. Treatment Trade-off
Pharmacoeconomics demonstrates the value of preventive interventions (vaccines, chemoprophylaxis) which have high upfront costs but generate substantial long-term savings by preventing expensive treatments and hospitalizations. This justifies investment in public health programs.
7. Identifying Dominant Strategies
By comparing new drugs against existing standards, pharmacoeconomics can identify when a new drug is both more effective AND less costly (dominant strategy) - the clearest argument for adoption - or when it costs more without meaningful added benefit (dominated strategy) - the clearest argument against.
8. Equity and Access
Budget impact analyses reveal whether cost-effective interventions are actually affordable at population scale, informing equity-conscious policies that ensure cost-effective drugs reach those who need them most.
SUMMARY TABLE
| Method | Cost Unit | Outcome Unit | Best Used When |
|---|---|---|---|
| Cost-Minimization | Monetary | Same for all strategies (assumed equal) | Outcomes proven equivalent |
| Cost-Benefit | Monetary | Monetary | Cross-sector resource allocation |
| Cost-Effectiveness | Monetary | Natural clinical units (LYG, cases cured) | Single disease, different outcomes |
| Cost-Utility | Monetary | QALYs | Cross-disease comparison, HTA |
| Cost-Consequence | Monetary | Multiple, presented individually | Multiple stakeholders, complex outcomes |
CONCLUSION
Pharmacoeconomic analysis provides a structured, evidence-based framework for evaluating the value of drug therapies beyond mere clinical efficacy. With healthcare budgets under increasing pressure worldwide, the ability to compare interventions using methods such as CMA, CBA, CEA, and CUA - all anchored by robust sensitivity analysis and decision modelling - is indispensable for every pharmacologist, clinician, and policy-maker. The QALY-based cost-utility analysis has emerged as the gold standard for health technology assessment, enabling rational, equitable allocation of limited healthcare resources across competing medical priorities.
Sources: Sabiston Textbook of Surgery (19e); Yamada's Textbook of Gastroenterology (7e); Rheumatology 2-Volume Set (Elsevier, 2022); Park's Textbook of Preventive and Social Medicine; Kaplan & Sadock's Comprehensive Textbook of Psychiatry
give me a short note for placebo for 5 marks for MD Pharmacology exam
Finding Sources
Finding Sources
Harrison's 22E has a dedicated chapter on placebo. Let me read those sections in parallel:
Reading File
Reading File
Reading File
Reading File
I have rich, authoritative content from Harrison's 22E (2025) and other sources. Here is the complete 5-mark short note:
PLACEBO
Definition
A placebo (Latin: "I shall please") is any substance or intervention that is pharmacologically inert but is presented to a patient as if it has therapeutic activity. Classically it is an inactive preparation (sugar pill, saline injection, sham surgery) identical in appearance to the active drug, given to a control group in clinical trials.
Types of Placebo
- Pure/Inert placebo - completely pharmacologically inactive (e.g., lactose tablet, normal saline injection)
- Impure placebo - pharmacologically active substance given in doses too small to have a specific pharmacological effect on the condition being treated (e.g., a small dose of vitamin C for pain)
The Placebo Effect (Placebo Response)
The placebo effect is the measurable, genuine psychobiological improvement in a patient's condition that results from the context of treatment rather than from any specific pharmacological action of the treatment. It is a real physiological phenomenon, not imaginary. - Maudsley Prescribing Guidelines, 15e
The total placebo response observed in clinical trials encompasses four components:
- The true placebo effect (psychological and biological)
- Natural history - spontaneous resolution of the disease (e.g., common cold resolving in 7-10 days)
- Regression to the mean - extreme baseline values statistically tend to improve toward the average
- Hawthorne effect - people change their behaviour when being observed
Mechanisms of the Placebo Effect
1. Psychological Mechanisms
- Expectations: The most important driver. Conscious belief that a treatment will work leads to genuine improvement. Even unconscious conditioning plays a role - patients repeatedly treated with active drugs develop conditioned placebo responses to the same context. - Harrison's Principles of Internal Medicine 22E
- Mindsets: Broader core beliefs (e.g., "I am in good hands," "this treatment works") shape patient experience and treatment outcomes beyond specific expectations.
2. Neurobiological Mechanisms
- Endogenous opioid system: Placebo analgesia is partially reversed by naloxone (opioid antagonist), proving endogenous opioid release underlies placebo pain relief. CCK-2 receptor antagonist proglumide enhances placebo analgesia. - Rheumatology, Elsevier
- Dopaminergic system: In Parkinson's disease, placebos activate dopamine release and D2/D3 receptors in the nucleus accumbens, producing genuine motor improvement.
- Brain circuits: fMRI studies show placebo activates the DLPFC, anterior cingulate cortex, PAG (periaqueductal grey), and limbic structures - the same descending pain inhibitory pathways activated by opioids.
3. Social and Cultural Mechanisms
- Clinician-patient interaction: Open administration of morphine with verbal reassurance ("this is a powerful painkiller") is 30% more effective than the same dose given covertly. Clinician warmth, competence, and empathy amplify placebo effects. - Harrison's 22E
- Drug appearance: Colour, size, brand name, route of administration, and cost all influence the magnitude of placebo response (e.g., injections > tablets; branded > generic).
The Nocebo Effect
The nocebo (Latin: "I shall harm") effect is the opposite of the placebo effect - negative expectations lead to genuine clinical worsening, adverse effects, or symptom emergence without any pharmacological cause. For example, patients warned about side effects of antidepressants and expecting harm report more adverse events. Mechanistically, nocebo hyperalgesia involves activation of CCK type-2 receptors and inhibition of μ-opioid receptors in the nucleus accumbens - the reverse of placebo analgesia. - Rheumatology, Elsevier; Maudsley Prescribing Guidelines
Role of Placebo in Clinical Trials
Placebos are the cornerstone of the randomized placebo-controlled double-blind trial (RCT), which is the gold standard for evaluating drug efficacy. The purpose is:
True drug effect = Total drug response - Placebo response
By subtracting the placebo response from the total response observed with active drug, the specific pharmacological effect of the drug is isolated. If the active treatment does not statistically outperform the placebo response, the drug is deemed to lack efficacy for FDA/regulatory approval.
Placebo controls also became institutionalized after the Declaration of Helsinki and Kefauver-Harris Amendments (1962), which mandated informed consent and rigorous drug evaluation. Placebos are not used when:
- A proven effective treatment already exists (active comparator is used instead)
- The condition is serious (e.g., active cancer), and withholding treatment is unethical
Clinical Uses of Placebo
- As a control in clinical drug trials
- To distinguish pharmacological from psychological components of a drug's effect
- Ethically harnessing the placebo effect by optimizing the therapeutic relationship, positive communication, and physician empathy - all of which genuinely improve patient outcomes
- Identifying and reducing the nocebo effect through careful, balanced disclosure of adverse effects
Key Points for Exam
| Feature | Detail |
|---|---|
| Definition | Pharmacologically inert substance given as if it has therapeutic activity |
| True placebo effect mechanism | Endogenous opioids, dopamine, expectation, conditioning |
| Nocebo | Negative expectation causing genuine harm; mediated by CCK/opioid antagonism |
| Reversed by | Naloxone (for placebo analgesia) |
| Role in trials | Isolates true pharmacological effect; controls for natural history, regression to mean, Hawthorne effect |
| Gold standard trial | Randomised, double-blind, placebo-controlled trial (RCT) |
Sources: Harrison's Principles of Internal Medicine 22E (2025, McGraw-Hill); Rheumatology 2-Volume Set (Elsevier, 2022); Maudsley Prescribing Guidelines in Psychiatry 15e
+12 more
Give me the list of questions from this system wise and also along with distribution of marks from the images
I can read the question papers clearly from the images you provided. Let me analyse all of them and compile the system-wise list.
analyse_media
analyse_media
analyse_media
analyse_media
analyse_media
analyse_media
analyse_media
I have all the content from all papers. The last two images (Paper II and Paper III of the Sep/Oct 2025 exam) were visible as visual input - I can read them directly. Let me now compile the complete system-wise breakdown.
MD Pharmacology — Question Papers: System-wise List with Marks
Source papers: SBKS MI&RC / Sumandeep Vidyapeeth
- Paper I (18-08-2025), Paper II (20-08-2025), Paper III (22-08-2025), Paper IV (25-08-2025) — Internal Exam
- Paper I (22-09-2025), Paper II (24-09-2025), Paper III (26-09-2025) — Sep/Oct University Exam
🔬 GENERAL PHARMACOLOGY & PHARMACOKINETICS
| Question | Marks | Paper |
|---|---|---|
| Explain individualisation of drug therapy with examples. Discuss targeted drug delivery systems. | 20 | Int. Paper I |
| Define clearance of a drug. How is it calculated? State clinical significance. Add a note on elimination kinetics. | 20 | Int. Paper I |
| Describe the role of various target proteins in drug action. Add a note on Types of receptors. | 20 | Int. Paper I |
| Second messenger (short note) | 10 | Int. Paper I |
| Structure-activity relationship (short note) | 10 | Int. Paper I |
| Explain the term 'Bioavailability.' Describe factors affecting bioavailability of oral drugs. Write a note on bioequivalence. | 20 | Univ. Paper I |
| Describe structure, activation mechanisms, and physiological roles of G-Protein Coupled Receptors (GPCRs) and their potential as therapeutic targets. | 20 | Univ. Paper I |
| Discuss the role of membrane transporters in pharmacodynamics of drugs (short note) | 10 | Univ. Paper I |
| Describe different types of drug antagonism, their mechanisms and clinical examples (short note) | 10 | Univ. Paper I |
💊 PHARMACOGENETICS / PHARMACOGENOMICS
| Question | Marks | Paper |
|---|---|---|
| Define pharmacogenomics. Discuss importance of pharmacogenetics with examples. | 20 | Int. Paper IV |
| Explain principles of pharmacogenetics, applications, benefits, and challenges in clinical practice. | 20 | Univ. Paper I |
🧠 CNS PHARMACOLOGY
| Question | Marks | Paper |
|---|---|---|
| Explain the monoamine theory of depression with pharmacological evidence. Mention types of antidepressants. Discuss pharmacological importance of SSRIs. | 20 | Int. Paper II |
| Classify analgesics. Describe adverse effects of morphine, precautions and contraindications. Add a note on aspirin (acetyl salicylic acid). | 20 | Int. Paper II |
| Dopaminergic agonists (short note) | 10 | Int. Paper II |
| Drug therapy of Alzheimer's disease (brief note) | 5 | Int. Paper II |
| Discuss in detail pathophysiology of Parkinsonism. Describe pharmacotherapy of Parkinson's disease. | 20 | Int. Paper III |
| Discuss the role of dopamine and its receptors as a therapeutic target. Include receptor types, mechanisms of action, and clinical applications of dopamine-related drugs. | 20 | Univ. Paper II |
🫀 CARDIOVASCULAR PHARMACOLOGY
| Question | Marks | Paper |
|---|---|---|
| History of digitalis (short note) | 10 | Int. Paper III |
| Discuss pathophysiology of congestive heart failure and recent trends in its management. | 20 | Int. Paper IV |
| New phosphodiesterase inhibitors and their clinical significance (brief note) | 5 | Int. Paper IV |
| Explain the Renin-Angiotensin-Aldosterone System (RAAS) and describe different classes of drugs acting on it, their mechanisms, therapeutic uses, and potential side effects. | 20 | Univ. Paper II |
🤢 GIT PHARMACOLOGY
| Question | Marks | Paper |
|---|---|---|
| Describe the reflex pathway of vomiting (with diagram). Classify antiemetic drugs by site/mechanism. Describe drug therapy of different types of vomiting. | 20 | Int. Paper II |
| Desmopressin (brief note) | 5 | Int. Paper II |
🫁 RESPIRATORY PHARMACOLOGY
| Question | Marks | Paper |
|---|---|---|
| Describe drugs used in bronchial asthma. Describe pathophysiology of asthma. Add a note on lab investigations. | 20 | Int. Paper III |
🦠 ANTIMICROBIALS / CHEMOTHERAPY
| Question | Marks | Paper |
|---|---|---|
| Classify beta-lactam antibiotics. Describe mechanism of action, therapeutic uses, and adverse drug reactions of cephalosporins. | 20 | Int. Paper III |
| Discuss treatment, problems and future aspects of non-retroviral infections. | 20 | Int. Paper IV |
| Recent advances in treatment of HIV infections (short note) | 10 | Int. Paper IV |
| Newer drugs for Malaria (brief note) | 5 | Univ. Paper II |
| Anti H. Pylori therapy (brief note) | 5 | Univ. Paper II |
🧬 IMMUNOPHARMACOLOGY / BIOLOGICALS / CANCER
| Question | Marks | Paper |
|---|---|---|
| Biological agents used in treatment of autoimmune diseases (short note) | 10 | Int. Paper III |
| Methotrexate (short note) | 10 | Int. Paper II |
| Recent advances in management of breast cancer (short note) | 10 | Int. Paper IV |
| Explain anticholinergic agents - therapeutics in various organ systems, adverse effects, contraindications, drug interactions; differences between naturally occurring, semisynthetic and synthetic anticholinergics. | 20 | Univ. Paper II |
| Describe role of methotrexate in clinical therapeutics (short note) | 10 | Univ. Paper II |
| Hormones used in treatment of malignancies (short note) | 10 | Univ. Paper II |
| Amphotericin B (brief note) | 5 | Univ. Paper II |
| Calcitonin Gene-Related Peptide (CGRP) targeted therapy in migraine (brief note) | 5 | Univ. Paper II |
🦴 ENDOCRINE / METABOLIC PHARMACOLOGY
| Question | Marks | Paper |
|---|---|---|
| Haemopoietic growth factors (brief note) | 5 | Int. Paper II |
| Topical steroids (brief note) | 5 | Int. Paper II |
| Current approaches in treatment of osteoporosis (brief note) | 5 | Int. Paper IV |
| Recent advances in management of obesity (brief note) | 5 | Int. Paper IV |
| Antioxidants (brief note) | 5 | Int. Paper IV |
🧪 CLINICAL PHARMACOLOGY / RATIONAL THERAPEUTICS
| Question | Marks | Paper |
|---|---|---|
| Placebo (brief note) | 5 | Int. Paper I |
| P-Drug (brief note) | 5 | Int. Paper I |
| Chronopharmacology (brief note) | 5 | Int. Paper I |
| Pharmacoeconomics (brief note) | 5 | Int. Paper I |
| Principles of drug dosing in geriatric patients (brief note) | 5 | Univ. Paper I |
| Orphan drugs (brief note) | 5 | Univ. Paper I |
| Role of Therapeutic Drug Monitoring (TDM) in patient care (brief note) | 5 | Univ. Paper I |
| P-drugs and how they are selected for rational prescribing (brief note) | 5 | Univ. Paper I |
🔬 RESEARCH METHODOLOGY / CLINICAL TRIALS / PHARMACOVIGILANCE
| Question | Marks | Paper |
|---|---|---|
| Guinea pig as an experimental animal (brief note) | 5 | Int. Paper III |
| Meta-analysis (brief note) | 5 | Int. Paper III |
| Bias in research (brief note) | 5 | Int. Paper III |
| Forest Plot (brief note) | 5 | Int. Paper III |
| Describe objectives, design, and key characteristics of various phases of clinical trials. | 20 | Univ. Paper III |
| Write in detail on ICH-GCP guidelines, their purpose, core principles, and significance in clinical research. | 20 | Univ. Paper III |
| Explain significance of spontaneous ADR reporting in pharmacovigilance. Explain methods used for causality assessment of reported ADRs. | 20 | Univ. Paper III |
| Explain various screening methods for evaluation of antiepileptic agents (short note) | 10 | Univ. Paper III |
| Describe the '3Rs' concept in animal experimentation (short note) | 10 | Univ. Paper III |
| Informed Consent (brief note) | 5 | Univ. Paper III |
| Placebo and its role in clinical trials (brief note) | 5 | Univ. Paper III |
| Small group discussions (SGD) and interactive sessions in medical education (brief note) | 5 | Univ. Paper III |
| Analysis of Variance (ANOVA) (brief note) | 5 | Univ. Paper III |
📊 MARKS DISTRIBUTION SUMMARY (per paper)
| Paper | Long Essays (20m each) | Short Notes (10m each) | Brief Notes (5m each) | Total |
|---|---|---|---|---|
| Int. Paper I | 3 × 20 = 60 | 2 × 10 = 20 | 4 × 5 = 20 | 100 |
| Int. Paper II | 3 × 20 = 60 | 2 × 10 = 20 | 4 × 5 = 20 | 100 |
| Int. Paper III | 3 × 20 = 60 | 2 × 10 = 20 | 4 × 5 = 20 | 100 |
| Int. Paper IV | 3 × 20 = 60 | 2 × 10 = 20 | 4 × 5 = 20 | 100 |
| Univ. Paper I | 3 × 20 = 60 | 2 × 10 = 20 | 4 × 5 = 20 | 100 |
| Univ. Paper II | 3 × 20 = 60 | 2 × 10 = 20 | 4 × 5 = 20 | 100 |
| Univ. Paper III | 3 × 20 = 60 | 2 × 10 = 20 | 4 × 5 = 20 | 100 |
Uniform pattern across all papers: Q1-Q3 = 20 marks each | Q4 = 2 × 10 marks | Q5 = 4 × 5 marks
High-frequency topics across papers (appeared more than once):
- Placebo - 2 papers
- P-Drugs / Rational prescribing - 2 papers
- Methotrexate - 2 papers
- Pharmacogenetics/Genomics - 2 papers
- Parkinson's disease / Dopamine - 2 papers
- Clinical trials / Research methodology - multiple papers
This is a shared conversation. Sign in to Orris to start your own chat.